
Medicines regulators in the USA, Europe and the UK have issued a mix of approvals, safety communications, a batch recall, guidance updates and public warnings over the past week. Generic drug policy, gene therapy and product quality defects account for most of the activity, with no CHMP meeting in August thinning the European approval pipeline.
The latest round-up includes an accelerated approval and two generic drug guidance actions from the US Food and Drug Administration (FDA), a direct healthcare professional communication and a high-profile application withdrawal from the European Medicines Agency (EMA), and a precautionary batch recall from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). The table below summarizes official human medicines regulatory updates from the past seven days.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze